fitusiran significantly reduces bleeding events in patients with hemophilia a or b, with inhibitors
Published 2 years ago • 330 plays • Length 3:04Download video MP4
Download video MP3
Similar videos
-
1:43
the safety and efficacy of fitusiran prophylaxis in patients with hemophilia a and b
-
1:48
the promise of fitusiran for the treatment of patients with hemophilia a and b
-
3:03
insights into the mechanism of action of fitusiran & the value of this agent in hemophilia treatment
-
1:23
the present and future of hemophilia a treatment
-
7:56
guy young: fitusiran for hemophilia a and b with inhibitors
-
4:43
novel treatments being explored for patients with hemophilia: highlights from isth 2024
-
3:29
fitusiran prophylaxis shows encouraging results in hemophilia patients
-
2:08
an overview of ongoing clinical trials for the treatment of hemophilia
-
2:16
determining when to switch from hydroxyurea to interferon-based therapy in patients with pv
-
1:09
highlights from isth: gene therapy in hemophilia a & undiagnosed bleeding disorders in pediatrics
-
0:39
promising therapeutic options emerging in hemophilia
-
9:36
hemophilia (year of the zebra)
-
1:51
treatment schedule for ruxolitinib in patients with mpns and how to assess response
-
20:08
hemophilia a - bleeding - most comprehensive explanation - hematology, bleeding, and coagulation
-
0:44
the role of social media in patient advocacy in hemophilia
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
5:00
long-term results of the phase ii revive study evaluating rusfertide in patients with pv
-
1:40
second-generation flt3 inhibitors in the treatment of flt3-itd aml